Addex Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Addex Therapeutics has a total shareholder equity of CHF11.1M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF12.2M and CHF1.1M respectively.
Key information
0%
Debt to equity ratio
CHF 0
Debt
| Interest coverage ratio | n/a |
| Cash | CHF 3.35m |
| Equity | CHF 11.06m |
| Total liabilities | CHF 1.11m |
| Total assets | CHF 12.17m |
Recent financial health updates
Recent updates
Addex, Indivior expand team up to develop therapies for substance use disorders
Aug 15Addex stock falls 11% amid $4.2M equity financing with Armistice
Jul 22Addex Therapeutics CEO Tim Dyer - Emerging Drugs For Central Nervous System (Video)
Oct 21Addex, Janssen initiate Phase 2 study of ADX71149 for epilepsy
Jun 07Addex Therapeutics reports Q1 results
May 05Addex drops 23% after pricing share offering
Jan 07Addex Therapeutics files to sell $10M of ADS
Dec 14Addex Therapeutics reports Q3 results
Nov 03Financial Position Analysis
Short Term Liabilities: ADXN's short term assets (CHF4.1M) exceed its short term liabilities (CHF887.6K).
Long Term Liabilities: ADXN's short term assets (CHF4.1M) exceed its long term liabilities (CHF218.5K).
Debt to Equity History and Analysis
Debt Level: ADXN is debt free.
Reducing Debt: ADXN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADXN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ADXN has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 10% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Addex Therapeutics Ltd is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Bob Pooler | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |